BIIB

#493
Biogen Inc. Common Stock
180.54 USD
+0.88%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
180.54
180.54
Faixa anual
114.66
202.41
Mudança diária
+0.88%
Mudança mensal
-2.27%
Mudança em 6 meses
+27.05%
Mudança anual
+56.73%
Fechamento anterior
178.96
Abrir
180.54
Bid
Ask
Mínimo
180.54
High
180.54
Volume
158
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 26.5 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry Fabricantes de medicamentos - gerais
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
20.02
Índice preço/fluxo de caixa
2.62

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Notícias